Beta blocker

Phase 3Small molecule

WWeill Medical College of Cornell University

Beta blocker is one of 108 small molecule programs targeting Catecholaminergic Polymorphic Ventricular Tachycardia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

107

Competitors

Pipeline

Status by Indication[3][1]

Indication

Catecholaminergic Polymorphic Ventricular TachycardiaActive, not recruiting

Post-Operative Atrial FibrillationActive, not recruiting

Acute Myocardial InfarctionActive, not recruiting

Coronary AtherosclerosisActive, not recruiting

Breast CancerActive, not recruiting

Chronic ConditionRecruiting

Aortic Valve StenosisRecruiting

HypertensiveRecruiting

Catecholaminergic Polymorphic Ventricular TachycardiaPreclinical

Active, not recruiting

Post-Operative Atrial FibrillationPreclinical

Active, not recruiting

Acute Myocardial InfarctionPreclinical

Active, not recruiting

Coronary AtherosclerosisPreclinical

Active, not recruiting

Breast CancerPreclinical

Active, not recruiting

Chronic ConditionPhase 3

Recruiting

Aortic Valve StenosisPhase 3

Recruiting

HypertensivePreclinical

Recruiting

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Beta blocker

WWeill Medical College of Cornell University

Phase 3

1 2

Blenoxane

Bristol-Myers Squibb

Preclinical

1 3

Lexiscan

Astellas

Preclinical

1 4

Voltaren

Novartis

Preclinical

1 5

Zolymbus

AbbVie

Preclinical

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 7

Spravato

WWim Janssens

Preclinical

2 8

Duragesic-100

CCephalon

Preclinical

2 9

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 10

Chantix

PPrism Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalNot yet recruiting

Study completion

NCT06509074

Q2 2027

Post-ApprovalRecruiting

Chronic Condition

NCT05786417

Recruiting

Glaucoma

NCT06993597

Q4 2027

ApprovedRecruiting

Heart Failure

NCT05585125

PreclinicalRecruiting

Coronary Atherosclerosis

NCT03504956

Q1 2028

ApprovedRecruiting

Aortic Valve Stenosis

NCT05721170

Clinical

Trials by Indication[1]

Heart Failure3 trials

Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy

Completed·—·Phase 4·NCT04575675·78 enrolled

Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart Failure

Unknown status·RRoyal Brompton & Harefield NHS Foundation Trust··NCT00832442·18,240 enrolled

A Preliminary Study for the Intervention of an N-of-1 Protocol For Medication Optimization

Recruiting·WWeill Medical College of Cornell University·Approved·NCT05585125·18 enrolled

Acute Myocardial Infarction2 trials

Influence of Beta Blockers on Prognosis in Patients With Acute Myocardial Infarction Complicated With Normal Ejection Fraction

Unknown status·—··NCT04485988·3,000 enrolled

The Contemporary Role of Beta Blockers in Patients With Acute Myocardial Infarction

Unknown status·—··NCT04564365·1,000 enrolled

Glaucoma2 trials

Collaborative Initial Glaucoma Treatment Study (CIGTS)

Unknown status·NNational Eye Institute (NEI)·Phase 3·NCT00000149

Development of Robust Corneal Biomechanical Biomarkers for Glaucoma Using Brillouin Microscopy

Recruiting·UUniversity of Maryland, Baltimore··NCT06993597·60 enrolled

Prevention1 trial

Asian Diabetes Outcomes Prevention Trial

Recruiting·NNational Heart Centre Singapore·Phase 4·NCT04286399·2,400 enrolled

Cardiac1 trial

BOAT: Beta Blocker Uptitration With OptiVol After Cardiac Resynchronization Therapy (CRT)

Terminated·SSt. Luke's-Roosevelt Hospital Center·Phase 4·NCT00433043·2 enrolled

16 more indications

Chronic Condition1 trial

LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions

Recruiting·YYale University·Phase 4·NCT05786417·741 enrolled

Hemodialysis1 trial

Removal of Beta Blocker Drugs by Hemodialysis

Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 1/2·NCT03361280·8 enrolled

Quality of Life1 trial

Role of Ivabradine on Heart Rate and Quality of Life in Patients With Mitral Stenosis in Sinus Rhythm

Completed·—·Phase 4·NCT06371222·42 enrolled

Tachycardia1 trial

Ivabradine Versus Beta-blockers in the Treatment of Inappropriate Sinus Tachycardia

Completed·PPoliclinico Casilino ASL RMB·Phase 3·NCT01657136·20 enrolled

Breast Cancer1 trial

Long-term Use of CCB and Breast Cancer Risk

Active, not recruiting·—··NCT05972785·68,500 enrolled

Post-Operative Atrial Fibrillation1 trial

Effect of Genetic Polymorphism on the Occurrence of Post-Operative Atrial Fibrillation After CABG

Completed·—··NCT03871647·256 enrolled

Randomized1 trial

Randomized Evaluation of Beta Blocker and ACEI/ARB Treatment in MINOCA Patients - MINOCA-BAT

Terminated·UUppsala University·Phase 4·NCT03686696·198 enrolled

Cardiovascular1 trial

Reducing Total Cardiovascular Risk in an Urban Community

Completed·JJohns Hopkins University·Phase 4·NCT00241904·525 enrolled

Hypertensive1 trial

Short-Term Effects of Antihypertensive Drugs on Postural Balance and Fall Risk

Recruiting·—·N/A·NCT07099677·186 enrolled

Catecholaminergic Polymorphic Ventricular Tachycardia1 trial

Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia

Completed·VVanderbilt University Medical Center·N/A·NCT01117454·14 enrolled

Myocardial Infarction1 trial

TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion"

Completed·FFundación Centro Nacional de Investigaciones Cardiovasculares Carlos III·Phase 4·NCT03596385·8,505 enrolled

Trial1 trial

Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).

Active, not recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 4·NCT05122780·120 enrolled

Aortic Valve Stenosis1 trial

Impact of Beta-blocker Continuation Versus Interruption in Patients Undergoing Transcatheter Aortic Valve Implantation

Recruiting·NNational and Kapodistrian University of Athens·Approved·NCT05721170·348 enrolled

Coronary Atherosclerosis1 trial

Coronary Atherosclerosis T1-Weighted Characterization (CATCH)

Recruiting·CCedars-Sinai Medical Center·Preclinical·NCT03504956·150 enrolled

Cardiac Amyloidosis1 trial

N-of-1 Trials to Promote Deprescribing in Older Adults With Transthyretin Cardiac Amyloidosis

Completed·WWeill Medical College of Cornell University·Approved·NCT05019027·14 enrolled

Unspecified1 trial

Beta-Blockers in Takotsubo Syndrome Study

Not yet recruiting·SSpanish Society of Cardiology·Phase 4·NCT06509074·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 25 trial records for Beta blocker. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Beta blocker compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Beta blocker. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Weill Medical College of Cornell University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: WWeill Medical College of Cornell University

Beta blocker

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q4 2027

Q1 2028

Trials by Indication[1]

Heart Failure3 trials

Acute Myocardial Infarction2 trials

Glaucoma2 trials

Prevention1 trial

Cardiac1 trial

Chronic Condition1 trial

Hemodialysis1 trial

Quality of Life1 trial

Tachycardia1 trial

Breast Cancer1 trial

Post-Operative Atrial Fibrillation1 trial

Randomized1 trial

Cardiovascular1 trial

Hypertensive1 trial

Catecholaminergic Polymorphic Ventricular Tachycardia1 trial

Myocardial Infarction1 trial

Trial1 trial

Aortic Valve Stenosis1 trial

Coronary Atherosclerosis1 trial

Cardiac Amyloidosis1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News